Associated Papers
HER2 mutation as an emerging target in advanced breast cancer.
Bon G et al.
Cancer Science, 2024
Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation.
Wang C et al.
Journal of the National Comprehensive Cancer Network : Jnccn, 2021
Targeting HER2 genomic alterations in non-small cell lung cancer.
Zeng J et al.
Journal of the National Cancer Center, 2021
Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review.
Qu Y et al.
Oncotargets and Therapy, 2021
Oncogenic mutations within the β3-αC loop of EGFR/ERBB2/BRAF/MAP2K1 predict response to therapies.
Zhang B et al.
Molecular Genetics & Genomic Medicine, 2020
Systematic response of staurosporine scaffold-based inhibitors to drug-resistant cancer kinase mutations.
He Y
Archiv Der Pharmazie, 2020
Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer.
Gaibar M et al.
Journal of Oncology, 2020
High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2.
Nagano M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.
Verma S et al.
Plos One, 2018
Genomic alterations of ERBB receptors in cancer: clinical implications.
Mishra R et al.
Oncotarget, 2017
Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature.
Petrelli F et al.
Breast Cancer Research and Treatment, 2017
Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.
Zuo WJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Select a paper to view details